Day: May 9, 2024

— Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc® for permanent non-surgical birth control continues — ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2024 and provides a corporate update. Corporate Highlights from 1Q 2024 to dateCompany announced positive topline data from pivotal trial for FDA-cleared FemaSeed® for the treatment of infertility. Company announced the first in-office commercial procedure with FDA-cleared FemaSeed infertility solution at a former investigative site. Appointed Richard...

COPENHAGEN, Denmark, May 09, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at the European Congress of Endocrinology being held May 11-14, 2024, in Stockholm. Topics include an oral presentation of new 2-year results from a post-hoc analysis of the Phase 3 PaTHway Trial demonstrating sustained improvements in kidney function in adults with chronic hypoparathyroidism treated with TransCon PTH, as well as a symposium presentation on health and quality-of-life improvements in patients switching from rhPTH(1-84) to TransCon PTH as part of a compassionate use program. “We are pleased to partner with leading experts in endocrinology to present...

First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv, to provide a gentler radiotherapy option to treat tumors in dogs and cats. This is the first commercial sale of the SRT-100 for veterinary use outside the U.S. Veterinary Specialist Referral Center Knowledge Farm was established in 2007 at Beit Berl College to provide imaging (ultrasound, CT and radiographs), general orthopedic soft tissue services and veterinary...

Refurbished Container ModulesRefurbished Container ModulesRefurbished Container Modules MIAMI, May 09, 2024 (GLOBE NEWSWIRE) — Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures, today announced it has received an expanded scope of work from a government contractor for a previously announced contract to refurbish 15 container modules to be used by a major U.S. government agency. Paul Galvin, Chairperson and CEO of Safe and Green Holdings stated, “We are always honored to work on behalf of our great military, directly and through other contractors. I am delighted to report that a key government contractor has broadened our previously announced engagement to refurbish 15 modular units with additional technological...

First quarter revenue of $13.2M, +27% year-over-year growth; IFRS gross margin of 75.2% First quarter pulse recurring revenue of $4.7M, +118% year-over-year growth    IFRS and non-IFRS operating loss narrowed to -$1.0M and -$0.4M, respectively; company approaching breakevenSAN CLEMENTE, Calif., May 09, 2024 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2024, for the period ended March 31, 2024, and recent business highlights. First Quarter Fiscal 2024 Financial HighlightsFirst Quarter Revenue of $13.2M; representing 27% year-over-year growthRecurring Revenue of $4.7M, a year-over- year increase of 118%, representing 36% of total revenue Gross Profit...

Pre-treatment Sample of Patient’s Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819 Translational Data from FT819 Phase 1 B Cell Malignancies Study Support Key Therapeutic Mechanisms of Activity for B Cell-mediated Autoimmune Diseases Initial Clinical Observations of FT522 CAR NK Cell Program in Phase 1 B Cell Lymphoma Study Show Rapid, Deep, and Sustained B Cell Depletion and Enhanced Persistence in the Periphery SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the first patient with systemic lupus erythematosus (SLE)...

OMER, Israel, May 09, 2024 (GLOBE NEWSWIRE) — Odysight.ai Inc. (OTCQB: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, is pleased to announce the receipt of a purchase order from Tel Aviv University for a research and development project of the Israeli Ministry of Defense for a bespoke system based on its proprietary visual sensors. Odysight believes the purchase order showcases the wide variety of applications for its visual know-how and proven expertise. Odysight.ai’s unique system provides a state-of-the-art solution, using advanced visual and processing capabilities, minimizing weight and size to meet challenging operating requirements. Odysight.ai’s unique technological capabilities and flexibility allow the rapid development of solutions to critical client...

JUPITER, FL, May 09, 2024 (GLOBE NEWSWIRE) — SRM Entertainment, Inc., (Nasdaq: SRM) (the “Company” or “SRM”) is pleased to announce a new regional theme park product order for our exclusive, colorful misting fans. The “fan favorite” is great to help beat the summer heat while your enjoying a fun day at one of America’s premier amusement parks. The 30,000+ unit order increases SRM’s expansion efforts with one of the largest regional amusement-resort operators in the world that welcomes approximately 28 million guests annually to parks located throughout the US. “SRM is striving to build relationships with premier entertainment destinations. Summertime is fun time for millions of people and we’re looking forward to helping them stay cool.” stated SRM’s CEO Rich Miller. About SRM Entertainment, Inc. SRM Entertainment designs, develops,...

First Quarter 2024 Revenue Totaled $12.6 Million, an increase of 10.4% Year-Over-Year First Quarter 2024 Net Income Attributable to Common Stockholders Totaled $6.9 Million, Funds from Operations Totaled $10.6 Million, and Adjusted Funds from Operations Totaled $11.0 Million Conference Call and Webcast Scheduled for May 9, 2024, at 11 a.m. Eastern Time NEW CANAAN, Conn., May 09, 2024 (GLOBE NEWSWIRE) — NewLake Capital Partners, Inc. (OCTQX: NLCP) (the “Company” or “NewLake”), a leading provider of real estate capital to state-licensed cannabis operators, today announced its financial results for the first quarter ended March 31, 2024. Anthony Coniglio, President and Chief Executive Officer, said, “We are pleased with the performance of our portfolio and financial results during the first quarter of 2024. Our growth in revenue and...

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET. A live webcast of the fireside chat will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation. About CRISPR TherapeuticsSince its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs...